AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...

Ultomiris (ravulizumab-cwvz) is a prescription drug approved to treat certain rare inflammatory conditions. Ultomiris comes as a liquid solution for intravenous (IV) infusion, which is given by a ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Ultomiris is already approved for the rare diseases Atypical Haemolytic Uremic Syndrome (aHUS), and Paroxysmal Nocturnal Haemoglobinuria, which at first glance would seem a million miles away from ...

Novartis has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal ...

The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Meanwhile, sales of Ultomiris, the flagship of AstraZeneca's Rare Disease segment and the successor of Soliris, reached $1.05 billion in the first three months of 2025, increasing by 22.2% year-on ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.